Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its target price increased by Citizens Jmp from $8.00 to $10.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price objective points to a potential upside of 192.40% from the stock’s previous close.

Several other research firms have also recently weighed in on IRWD. Wells Fargo & Company boosted their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Citigroup raised shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.93.

Ironwood Pharmaceuticals Trading Down 6.6%

Shares of Ironwood Pharmaceuticals stock opened at $3.42 on Thursday. The firm has a fifty day simple moving average of $4.28 and a 200-day simple moving average of $2.82. The stock has a market capitalization of $556.37 million, a price-to-earnings ratio of 26.31 and a beta of 0.17. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.03). The firm had revenue of $47.71 million during the quarter, compared to the consensus estimate of $86.10 million. Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%. As a group, research analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 76.1% during the second quarter. Los Angeles Capital Management LLC now owns 1,211,155 shares of the biotechnology company’s stock valued at $869,000 after acquiring an additional 523,368 shares during the period. Focus Partners Advisor Solutions LLC lifted its position in Ironwood Pharmaceuticals by 284.6% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 29,409 shares during the period. Armistice Capital LLC boosted its stake in shares of Ironwood Pharmaceuticals by 17.9% in the 2nd quarter. Armistice Capital LLC now owns 16,150,000 shares of the biotechnology company’s stock valued at $11,583,000 after purchasing an additional 2,450,000 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Ironwood Pharmaceuticals by 26.0% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 526,775 shares of the biotechnology company’s stock worth $378,000 after buying an additional 108,822 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Ironwood Pharmaceuticals by 48.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,206,948 shares of the biotechnology company’s stock worth $1,583,000 after buying an additional 718,904 shares during the last quarter.

Key Ironwood Pharmaceuticals News

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Analyst price-target lift from Citizens JMP — Citizens JMP raised its price target to $10 and kept a “market outperform” rating, signaling significant upside potential if execution or pipeline news turns favorable. Read More.
• Neutral Sentiment: Q4 earnings call highlighted continued strength in LINZESS sales even as overall revenue fell; investors will watch whether LINZESS can stabilize top-line trends going forward. Read More.
• Neutral Sentiment: Post-quarter valuation and 2026 revenue guidance analysis is prompting re‑rating discussions — analysts and commentators are reworking models after the miss, which could amplify volatility while estimates are adjusted. Read More.
• Neutral Sentiment: Market commentaries explaining the share drop (e.g., coverage pieces) are framing the move as a reaction to the earnings miss plus guidance/pipeline uncertainty rather than a single catalyst. Read More.
• Negative Sentiment: Pipeline setback for apraglutide and an extended development timeline — Seeking Alpha and other analysts lowered expectations after management pushed timelines, increasing risk to future upside from the pipeline. Read More.
• Negative Sentiment: Q4 results missed estimates — IRWD reported a loss for the quarter, with revenue falling ~47% YoY and coming in well below consensus, which directly triggered the share sell-off. Read More.
• Negative Sentiment: Zacks Research downgraded IRWD from “strong-buy” to “hold,” removing a supportive endorsement and adding selling pressure amid the disappointing quarter. Read More.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.